These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33711401)

  • 1. Preclinical models and technologies to advance nanovaccine development.
    Peres C; Matos AI; Moura LIF; Acúrcio RC; Carreira B; Pozzi S; Vaskovich-Koubi D; Kleiner R; Satchi-Fainaro R; Florindo HF
    Adv Drug Deliv Rev; 2021 May; 172():148-182. PubMed ID: 33711401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
    Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
    [No Abstract]   [Full Text] [Related]  

  • 3. Personalized cancer vaccines: adjuvants are important, too.
    Gouttefangeas C; Rammensee HG
    Cancer Immunol Immunother; 2018 Dec; 67(12):1911-1918. PubMed ID: 29644387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
    Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
    Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy.
    Tiptiri-Kourpeti A; Spyridopoulou K; Pappa A; Chlichlia K
    Pharmacol Ther; 2016 Sep; 165():32-49. PubMed ID: 27235391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Vaccines Designed Based the Nanoparticle and Tumor Cells for the Treatment of Tumors: A Perspective.
    Wu QJ; Lv WL
    IET Nanobiotechnol; 2024; 2024():5593879. PubMed ID: 38863969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
    Guo Y; Chen Y; Liu X; Min JJ; Tan W; Zheng JH
    Cancer Lett; 2020 Jan; 469():102-110. PubMed ID: 31666180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of adjuvants for immunotherapy.
    Circelli L; Tornesello M; Buonaguro FM; Buonaguro L
    Hum Vaccin Immunother; 2017 Aug; 13(8):1774-1777. PubMed ID: 28604160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccines: between the idea and the reality.
    Finn OJ
    Nat Rev Immunol; 2003 Aug; 3(8):630-41. PubMed ID: 12974478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Vaccines, Adjuvants, and Delivery Systems.
    Paston SJ; Brentville VA; Symonds P; Durrant LG
    Front Immunol; 2021; 12():627932. PubMed ID: 33859638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifunctional nanoparticles for cancer immunotherapy.
    Saleh T; Shojaosadati SA
    Hum Vaccin Immunother; 2016 Jul; 12(7):1863-75. PubMed ID: 26901287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
    Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
    Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer immunotherapy and nanomedicine.
    Sheng WY; Huang L
    Pharm Res; 2011 Feb; 28(2):200-14. PubMed ID: 20821040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current challenges for cancer vaccine adjuvant development.
    Bowen WS; Svrivastava AK; Batra L; Barsoumian H; Shirwan H
    Expert Rev Vaccines; 2018 Mar; 17(3):207-215. PubMed ID: 29372660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methods for improving the immunogenicity and efficacy of cancer vaccines.
    Pilla L; Ferrone S; Maccalli C
    Expert Opin Biol Ther; 2018 Jul; 18(7):765-784. PubMed ID: 29874943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
    Hamdy S; Haddadi A; Hung RW; Lavasanifar A
    Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining therapeutic vaccines with chemo- and immunotherapies in the treatment of cancer.
    Kerr MD; McBride DA; Chumber AK; Shah NJ
    Expert Opin Drug Discov; 2021 Jan; 16(1):89-99. PubMed ID: 32867561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape.
    Garg AD; Coulie PG; Van den Eynde BJ; Agostinis P
    Trends Immunol; 2017 Aug; 38(8):577-593. PubMed ID: 28610825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
    Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
    Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.